AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer.
Ceralasertib is an oral ATR kinase inhibitor designed to enhance anti-tumor immune activity, while Imfinzi is a PD-L1 inhibitor approved for multiple lung and other cancers. AstraZeneca said the combination was generally well tolerated and that no new safety concerns were identified, according to a Dec. 22 news release from the company.
The global trial enrolled 594 patients across more than 20 countries. It studied patients with locally advanced or metastatic non-small cell lung cancer without actionable genomic alterations whose disease had progressed following immunotherapy and platinum-based chemotherapy. Participants were randomized to receive ceralasertib and Imfinzi or standard-of-care docetaxel.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
